Signatera™ for Testicular Cancer

Tumor-informed ctDNA testing may provide prognostic insight in patients with germ cell tumors.

Order Signatera™

Personalized ctDNA insights in testicular cancer

Signatera™ enables risk stratification and disease monitoring in testicular cancer.¹

Identify

high-risk patients

>5×

higher risk of recurrence.¹

Early detection

during surveillance

>12×

higher likelihood of relapse.¹

Superior

to serum tumor markers

100%

vs 0% recurrence in discordant cases.¹

Superior prognostic insight beyond serum tumor markers

Serum tumor markers such as AFP, β-hCG, and LDH are routinely used in testicular cancer management, but are normal in up to 40% of patients and can be falsely elevated.¹

Tumor-informed ctDNA testing with Signatera™ may provide a more sensitive and specific approach to detecting molecular residual disease and recurrence.¹

SGN_WB_MD_Testicular_20260203_NAT-8023522_TextImage

Largest ctDNA cohort in testicular cancer to date

Clinical validation in testicular cancer demonstrates Signatera™ ctDNA testing’s ability to identify patients at highest risk of recurrence across disease stages and clinical windows.

Clinically validated in testicular cancer

Multi-institutional clinical evidence demonstrates Signatera™ ctDNA testing’s prognostic value in testicular cancer.¹

SGN_WB_MD_Testicular_20260203_NAT-8023522_VerticalTab-01

Post-Orchiectomy MRD Window

ctDNA-positive patients had >5× higher recurrence risk compared with ctDNA-negative patients.¹
ctDNA positivity during the MRD window was associated with significantly inferior event-free survival (HR=5.11; p=0.019).¹

SGN_WB_MD_Testicular_20260203_NAT-8023522_VerticalTab-03

ctDNA vs Serum Tumor Markers

In the surveillance dataset, all ctDNA-positive/STM-negative patients recurred.¹
In contrast, no ctDNA-negative/STM-positive patients recurred.¹
ctDNA status—not serum tumor markers—drove recurrence risk during surveillance.¹

FAQs

How does Signatera™ compare to serum tumor markers in testicular cancer?

Signatera™ demonstrated superior prognostic performance compared with AFP, β-hCG, and LDH. During surveillance ctDNA status, not serum tumor markers, drove recurrence risk.¹

When should Signatera™ be used in testicular cancer?

Signatera™ can be used post-orchiectomy to assess molecular residual disease and during surveillance to monitor for recurrence and guide clinical decision-making.¹

Is Signatera™ for Testicular Cancer right for your patients?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Hassoun R, et al. Longitudinal Evaluation of Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors. JCO Precision Oncology. 2025.